Dr. Jane Salmon is the Collette Kean Research Professor at Hospital for Special Surgery. She is Professor of Medicine and Professor of Medicine in Obstetrics and Gynecology and Associate Dean, Faculty Affairs at Weill Cornell College of Medicine.
Dr. Salmon graduated magna cum laude from New York University and earned a medical degree in 1978 from the College of Physicians and Surgeons of Columbia University, where she was the first woman enrolled in their Medical Scientist Training Program. She completed training in internal medicine at The New York Hospital and in rheumatology at Hospital for Special Surgery, where she currently conducts clinical and basic research studies and practices rheumatology. Dr. Salmon has served on the Board of Directors of the American College of Rheumatology and Rheumatology Research Foundation. Dr. Salmon was co-editor of Arthritis and Rheumatism and is currently an Associate Editor of Annals of Rheumatic Diseases. At Hospital for Special Surgery, she is a Director of the Lupus and APS Center of Excellence, Co-Director of the Mary Kirkland Center for Lupus Research.
Dr. Salmon’s research has focused on elucidating mechanisms of tissue injury in lupus and other autoimmune diseases. Her basic, translational and clinical studies have led to a paradigm shift in the understanding of mechanisms of pregnancy loss, cardiovascular disease and end-organ damage in patients with lupus. She identified the critical role of inflammation as a mediator of placental insufficiency and defined new treatment targets.
Attending Physician, Hospital for Special Surgery
Collette Kean Research Chair, Hospital for Special Surgery
Director, SLE APS Center of Excellence, Hospital for Special Surgery
Senior Scientist, Hospital for Special Surgery
Co-Director, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery
Professor of Medicine, Weill Cornell Medical College
Professor of Medicine in Obstetrics and Gynecology, Weill Cornell Medical College
Professor, Graduate Program in Microbiology and Immunology, Weill Cornell Graduate School of Medical Sciences
Associate Dean of Faculty Affairs, Weill Cornell Medicine
Systemic Lupus Erythematosus
Elected member, National Academy of Medicine, 2016
Master, American College of Rheumatology, 2017
Evelyn Hess Award, Lupus Foundation of America, 2014
Swartz Lectureship, Swedish Society of Medicine, 2012
Virginia Kneeland Frantz ’22 Distinguished Women in Medicine Award, Columbia P&S Alumni Association, 2012
New York Magazine: Top Doctors: 2013, 2012, 2009, 2004
American Association of Physicians 2008
Carol Nachman Prize in Rheumatology (most prestigious international award for rheumatology), 2007
Theodore E. Woodward Award, American Clinical and Climatological Association, 2007
Scientific Advisory Board, Lupus Research Alliance
Associate Dean, Faculty Affairs, Weill Cornell Medicine
Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may still have coverage subject to the availability of 'out-of-network' benefits.
Dr. Salmon accepts the following insurance plans:
Please note, if your insurance is not on this list, you may still have coverage subject to the availability of out-of-network benefits.
If you do not wish to go out-of-network, our Physician Referral Service will help you find an appropriate doctor.
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Salmon as of March 23, 2018.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.
Salmon JE, Pricop L, D’Agati V: Immunopathology of SLE. In: Rheumatology 6th Edition, edited by MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, M Weisman. Mosby, London, pp 1253-1270, 2015.
Salmon JE: Mechanisms of immune-mediated tissue injury. in: Cecil Textbook of Medicine (25th edition), edited by L Goldman and AI Schafer, Elsevier Saunders, Philadelphia, pp 226-230, 2015.
Erkan D, Salmon JE, Lockshin MD. Anti-phospholipid Syndrome. In: Kelley’s Textbook of Rheumatology, 10th Edition, edited by GS Firestein, RC Budd, SE Gabriel, IB McInnes and JR O’Dell. Elsevier Saunders, Philadelphia, pp1389-1399, 2016.
Qing X, Chinenov Y, Redecha P, Madaio M, Roelofs JJ, Farber G, Issuree PD, Donlin L, Mcllwain DR, Mak TW, Blobel CP, Salmon JE. iRhom2 promotes lupus nephritis through TNF-α and EGFR signaling. J Clin Invest. 2018 Mar 5. pii: 97650. doi: 10.1172/JCI97650. [Epub ahead of print].
Kim MY, Guerra MM, Kaplowitz E, Laskin CA, Petri M, Branch DW, Lockshin MD, Sammaritano LR, Merrill JT, Porter TF, Sawitzke A, Lynch AM, Buyon JP, Salmon JE. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018 Apr;77(4):549-555. doi: 10.1136/annrheumdis-2017-212224. Epub 2018 Jan 25.
Kim, MY, Buyon JP, Guerra, MM, Rana S, Zhang D, Laskin CA, Petri M, Lockshin MD, Sammaritano, LR, Branch, DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: Results of the PROMISSE study. Am J Obstet Gynecol 214: 108.e1-108.e14, 2016 [ePub 2015 Sept 29].
Buyon JP, Kim YM, Guerra MM, Laskin CA, Petri M, Lockshin, MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E; Garabet L, Salmon JE. Predictors of pregnancy outcome in a prospective, multiethnic cohort of lupus patients. Ann Intern Med 163: 153-163, 2015 (ePub 23 June).
Issuree PDA, Maretzky T, McIlwain DR, Monette S, Qing X, Lang P, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD, Yarilina A, Horiuchi K, Ivashkiv LB, Mak TW, Salmon JE*, Blobel CP*. IRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest 123:928-32, ePub Jan 25, 2013 *equal contribution.
Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 64:307-24, 2013.
Isgro J, Gupta S, Jacek E, Pavri T, Duculan R, Kim M, Kirou K, Salmon JE, Pernis AB. Enhanced ROCK activation in patients with systemic lupus erythematosus. Arthritis Rheum 65:1592-602, 2013
Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter F, Sammaritano L, Stephenson MD, Buyon J, Salmon JE. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody in patients with antiphospholipid antibodies. Arthritis Rheum 64:2311-18, 2012
Lynch AM, Salmon JE. Dysregulated Complement Activation as a Common Pathway of Injury in Preeclampsia and Other Pregnancy Complications. Placenta 31: 562-567, 2010
Roman MJ, Salmon JE. Cardiovascular Manifestations of Rheumatologic Diseases. Circulation 116: 2346-2355, 2007.
Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement Activation Induces Dysregulation of Angiogenic Factors and Causes Fetal Rejection and Growth Restriction. J Exp Med 203: 2165-2175, 2006.
Roman M, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Schwartz JE, Levine DM, Salmon JE. Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis: Prevalence and Associated Factors. Ann Intern Med 144: 249-256, 2006.
Girardi G, Redecha PB, Salmon JE. Heparin Prevents Antiphospholipid Antibody-induced Fetal Loss by Inhibiting Complement Activation. Nat Med 10: 1222-6, 2004.
Roman, MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. New Engl J Med 349: 2399-406, 2003.
Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a Receptors and Neutrophils Mediate Fetal Injury in the Antiphospholipid Syndrome. J Clin Invest 112: 1644-54, 2003.
For more publications, please see the PubMed listing.
3rd Graciela S. Alarcon MD, MPH, Lecture, University of Alabama at Birmingham, 2016
Mary Jane Keller Lectureship, Yale School of Medicine 2016
Kroc Lectureship, Washington University, St. Louis, 2015
Nanna Swartz Lectureship. Swedish Medical Society, 2012
Annual Ogryzlo Research Day Visiting Professor, University of Toronto, Division of Rheumatology, 2012
Soderberg Prize Symposium, Swedish Society of Medicine, Stockholm, 2010
Eric Bywaters Memorial Lecture, Imperial College of London, 2007
Edmund L. Dubois, MD, Memorial Lectureship Award, American College of Rheumatology, 2004
The goal of Dr. Salmon’s research is to identify predictors and determinants of disease phenotype in systemic lupus erythematosus (SLE) and related diseases, and to thereby identify targets for therapy. In SLE and other autoimmune diseases, autoantibodies and immune complexes initiate inflammation and organ damage through receptors for IgG and complement activation products. The laboratory investigates downstream mediators and effector mechanisms of tissue injury. Their basic, translational and clinical studies have led to a paradigm shift in the understanding of mechanisms of pregnancy loss, cardiovascular disease and nephritis in patients with SLE. This work to define pathogenic mechanisms in SLE is likely to translate to non-autoimmune patients.
Dr. Salmon’s laboratory defined structure-function relationships among human receptors for IgG, key effectors in immune-complex diseases and showed that allelic variants were risk factors for nephritis. She led the first case-control study to define prevalence and clinical correlates of pre-clinical atherosclerosis in SLE and found accelerated and premature disease, independent of traditional cardiovascular risk factors, rather related to inflammation.
Building on her discovery that innate immune pathways, complement, neutrophils and TNF-α, are critical effectors of pregnancy complications in mouse models, she led an NIH-funded, multi-center 11 year prospective longitudinal study of 700 pregnant patients to identify predictors of pregnancy outcomes in patients with lupus and/or anti-phospholipid syndrome. She has now embarked on the first interventional trial of biologic therapy to protect pregnancies at high risk for preeclampsia, an approach likely to have broad public health implications.